CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight
CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight
Multiple Myeloma Market to Witness Substantial Growth -- Key Trends and Forecasts of Different Reports for the Next Decade | DelveInsight
Multiple Myeloma Market to Witness Substantial Growth -- Key Trends and Forecasts of Different Reports for the Next Decade | DelveInsight
Legend Biotech Co. (NASDAQ: LEGN) had its price target lowered by analysts at Morgan Stanley from $82.00 to $80.00. They now have an "overweight" rating on the stock.